MedPath

Obexelimab

Generic Name
Obexelimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1690307-05-1
Unique Ingredient Identifier
RM16A4BA8R
Background

Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).

Associated Conditions
-
Associated Therapies
-

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Phase 2
Recruiting
Conditions
Relapsing Multiple Sclerosis
Interventions
Drug: Obexelimab
Drug: Placebo
First Posted Date
2024-08-21
Last Posted Date
2025-01-06
Lead Sponsor
Zenas BioPharma (USA), LLC
Target Recruit Count
93
Registration Number
NCT06564311
Locations
🇺🇸

University of Massachusetts Medical School, Worcester, Massachusetts, United States

🇨🇿

Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia

🇺🇸

Regina Berkovich MD PhD, Inc, West Hollywood, California, United States

and more 27 locations

A Study of Obexelimab in Patients with Systemic Lupus Erythematosus

Phase 2
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Placebo
Drug: Obexelimab
First Posted Date
2024-08-19
Last Posted Date
2025-01-07
Lead Sponsor
Zenas BioPharma (USA), LLC
Target Recruit Count
190
Registration Number
NCT06559163
Locations
🇧🇬

University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv", Plovdiv, Bulgaria

🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

and more 32 locations
© Copyright 2025. All Rights Reserved by MedPath